Asher Biotherapeutics, Inc.
Asher Biotherapeutics is pioneering a new approach with cis-targeted immunotherapies, focusing on selectively activating immune cell types to improve efficacy and reduce side effects. Their platform aims to transform immunotherapy by delivering highly precise treatments for cancer and other diseases, with a strong commitment to patient impact and innovative science.
Industries
Nr. of Employees
small (1-50)
Asher Biotherapeutics, Inc.
650 Gateway Blvd. Suite 100, South San Francisco, CA 94080
Products
Lead CD8-targeted IL-2 clinical candidate (Phase 1a/1b)
A CD8-selective interleukin-2 therapeutic candidate engineered to stimulate IL-2 receptor activity on CD8+ T cells while minimizing activation of NK and regulatory T cells.
CD8-targeted IL-21 preclinical candidate
A CD8-targeted interleukin-21 construct designed to selectively enhance CD8+ T cell cytotoxic function through a pathway complementary to IL-2.
CD8-targeted IL-2 candidate for chronic infectious disease (preclinical)
A CD8-targeted IL-2 program developed for potential treatment of chronic viral infection indications.
Lead CD8-targeted IL-2 clinical candidate (Phase 1a/1b)
A CD8-selective interleukin-2 therapeutic candidate engineered to stimulate IL-2 receptor activity on CD8+ T cells while minimizing activation of NK and regulatory T cells.
CD8-targeted IL-21 preclinical candidate
A CD8-targeted interleukin-21 construct designed to selectively enhance CD8+ T cell cytotoxic function through a pathway complementary to IL-2.
CD8-targeted IL-2 candidate for chronic infectious disease (preclinical)
A CD8-targeted IL-2 program developed for potential treatment of chronic viral infection indications.
Services
In-house discovery and engineering of cell-type selective immunomodulator constructs by combining attenuated immunomodulators with targeting moieties.
Partnerships to enable combination studies, provide clinical supply, and support multi-site Phase 1 studies.
Process development, formulation, manufacturing and distribution services to support clinical trial material production and supply chain for investigational biologics.
Regulatory strategy, filing preparation and consultation informed by in-house and external regulatory expertise.
In-house discovery and engineering of cell-type selective immunomodulator constructs by combining attenuated immunomodulators with targeting moieties.
Partnerships to enable combination studies, provide clinical supply, and support multi-site Phase 1 studies.
Process development, formulation, manufacturing and distribution services to support clinical trial material production and supply chain for investigational biologics.
Regulatory strategy, filing preparation and consultation informed by in-house and external regulatory expertise.
Expertise Areas
- Cis-targeted immunotherapy discovery
- Protein engineering and affinity/avidity tuning
- Cytokine therapeutic development
- Preclinical efficacy and translational studies
Key Technologies
- Cis-targeted immunomodulation
- Cytokine engineering
- Affinity attenuation and avidity-based activation
- Targeting-moiety fusion constructs